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Abstract
Background: Alzheimer's disease (AD) is characterized by a decline in cognitive function and
accumulation of amyloid-β peptide (Aβ) in extracellular plaques. Mutations in amyloid precursor
protein (APP) and presenilins alter APP metabolism resulting in accumulation of Aβ42, a peptide
essential for the formation of amyloid deposits and proposed to initiate the cascade leading to AD.
However, the role of Aβ40, the more prevalent Aβ peptide secreted by cells and a major
component of cerebral Aβ deposits, is less clear. In this study, virally-mediated gene transfer was
used to selectively increase hippocampal levels of human Aβ42 and Aβ40 in adult Wistar rats,
allowing examination of the contribution of each to the cognitive deficits and pathology seen in AD.
Results: Adeno-associated viral (AAV) vectors encoding BRI-Aβ cDNAs were generated resulting
in high-level hippocampal expression and secretion of the specific encoded Aβ peptide. As a
comparison the effect of AAV-mediated overexpression of APPsw was also examined. Animals
were tested for development of learning and memory deficits (open field, Morris water maze,
passive avoidance, novel object recognition) three months after infusion of AAV. A range of
impairments was found, with the most pronounced deficits observed in animals co-injected with
both AAV-BRI-Aβ40 and AAV-BRI-Aβ42. Brain tissue was analyzed by ELISA and
immunohistochemistry to quantify levels of detergent soluble and insoluble Aβ peptides. BRI-Aβ42
and the combination of BRI-Aβ40+42 overexpression resulted in elevated levels of detergent-
insoluble Aβ. No significant increase in detergent-insoluble Aβ was seen in the rats expressing
APPsw or BRI-Aβ40. No pathological features were noted in any rats, except the AAV-BRI-Aβ42
rats which showed focal, amorphous, Thioflavin-negative Aβ42 deposits.
Conclusion: The results show that AAV-mediated gene transfer is a valuable tool to model
aspects of AD pathology in vivo, and demonstrate that whilst expression of Aβ42 alone is sufficient
to initiate Aβ deposition, both Aβ40 and Aβ42 may contribute to cognitive deficits.
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Background
Alzheimer's disease (AD) is a prevalent neurodegenerative
disorder characterized by a decline in cognitive function,
accumulation of extracellular amyloid-β peptides (Aβ)
and intracellular neurofibrillary tangles, and neuronal
loss. Numerous AD-linked mutations in amyloid precur-
sor protein (APP) and presenilins (PS) [1-3] alter APP
metabolism resulting in accumulation of Aβ42, a 42-
amino acid product essential for the formation of paren-
chymal and vascular amyloid deposits [4], and proposed
to initiate the cascade leading to AD [3]. However, the role
of Aβ40, the more prevalent Aβ peptide secreted by cells
and a major component of deposits in the cerebral vascu-
lature of AD brain [5,6], is less clear.
Current transgenic models of AD utilize overexpression of
mutant human APP and PS1 to increase Aβ production
and recapitulate AD cognitive deficits and pathologies [7-
10]. However, overexpression of APP results not only in
increased production of both Aβ40 and Aβ42, but in ele-
vated levels of other APP fragments which can have neu-
roprotective [11,12], neurotoxic [13] or signaling
functions [14] and influence learning and memory [15-
18]. In this study we have used adeno-associated viral
(AAV) vectors, gene transfer agents that result in stable,
long-term transgene expression in neurons [19-21], to tar-
get expression of individual Aβ peptides to the hippocam-
pus of adult rats, allowing us to examine the role of each
in the pathology and cognitive deficits seen in AD models.
The use of viral vectors to overexpress genes implicated in
disease pathogenesis has already been successfully imple-
mented to generate non-transgenic rat models of both
Parkinson's [22,23] and Huntington's diseases [24,25],
with successful transfer of the method to a primate model
[26].
AAV1 vectors encoding BRI-Aβ cDNAs, fusions between
human Aβ peptides and the BRI protein involved in amy-
loid deposition in British and Danish familial dementia
[27,28], were used to achieve high-level hippocampal
expression and secretion of the specific encoded Aβ pep-
tide [4,29] in the absence of APP overexpression. As a
comparison we also examined the effect of AAV-mediated
overexpression of APPsw (APP containing the Swedish
mutations, K670N and M671L). AAV-treated animals
were tested for development of cognitive deficits, and
brain tissue analyzed for Aβ levels and evidence of extra-
cellular Aβ deposition. The results show that AAV-medi-
ated gene transfer is a valuable tool to model aspects of
AD pathology in vivo, and demonstrate that whilst virally-
mediated overexpression of Aβ42 alone is sufficient to ini-
tiate plaque deposition, both Aβ40 and Aβ42 levels con-
tribute to the development of cognitive deficits in this
model.
Results
Infusion of AAV-BRI-Aβ vectors increases hippocampal Aβ 
expression
AAV1 vectors encoding APPsw and BRI-Aβ42 or BRI-Aβ40
fusion proteins were generated and injected bilaterally
into the hippocampus of adult rats, alone and in combi-
nation. Brain tissue was examined for presence of trans-
gene expression three weeks later. As seen in Figure 1,
infusion of vectors resulted in widespread expression of
the transgene in neurons throughout the hippocampus,
detectable by immunohistochemistry using an antibody
to human Aβ, residues 1–17 (6E10). AAV-BRI-Aβ42, AAV-
BRI-Aβ40 and combined AAV-BRI-Aβ40+42 injected
brains had extensive transgene expression in the rostral-
caudal axis, extending ~2 mm on either side of the injec-
tion site, and throughout the layers of the hippocampus.
In these brains the granule cell and molecular layers of the
dentate gyrus and pyramidal cells of CA1 were transduced
(Figure 1). More variable transduction levels were seen in
CA2-CA4 subfields and hilar interneurons. In contrast, no
transgene expression was observed in naïve (non-
injected) rat brain. Given the lack of specific antibodies
for the furin-cleaved BRI protein, it is not possible to dis-
tinguish whether the staining reflects Aβ or the BRI-Aβ
fusion proteins. However, based on ELISA data (see
below) and previous studies in transgenic mice, it is clear
that the BRI-fusion proteins result in enhanced produc-
tion of the encoded Aβ peptide [4].
In AAV-APPsw brains, Aβ immunostaining extended as far
in the rostral-caudal direction as in BRI-Aβ fusion ani-
mals, but staining was not as widespread within the layers
of hippocampus. These brains contained much lower
expression levels in the granule cells of dentate gyrus and
CA1 (Figure 1) than that observed in BRI-Aβ fusion
brains, with no positive immunostaining in CA2-4 or
hilar interneurons. Distinctive sub-cellular expression pat-
terns were observed with the different vectors – transgene
detected following transduction with the BRI-Aβ40 and
BRI-Aβ42 vectors filled the cell bodies; transduction
obtained with the APPsw vector resulted in sparse trans-
gene expression within the cell soma but expression
extended out into the processes.
Animals treated with AAV vectors encoding BRI-Aβ fusions 
develop cognitive deficits
Once hippocampal transgene expression had been con-
firmed in a small number of test animals, further animals
were injected with AAV vectors and tested for develop-
ment of cognitive deficits at 3 months post-infusion. In
the open field, naive animals crossed an average of ~130
lines in a 5 min period; BRI-Aβ42, BRI-Aβ40 and APPsw
animals crossed a comparable number of lines with mean
line crosses in these groups of ~140 (Figure 2A). However
BRI-Aβ40+42 animals crossed significantly more linesMolecular Neurodegeneration 2007, 2:11 http://www.molecularneurodegeneration.com/content/2/1/11
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Transgene expression in rat hippocampus, 3 weeks post-infusion Figure 1
Transgene expression in rat hippocampus, 3 weeks post-infusion. A group of test animals (n = 3 per group) was 
injected with AAV1 vectors and brains analysed for transgene expression (anti-amyloid beta protein, Chemicon, MAB1560, 
6E10, specific for human Aβ). No Aβ expression was observed in naïve rat brain. Infusion of AAV1 vectors expressing BRI-
Aβ42 and BRI-Aβ40 fusions or APPsw resulted in extensive expression of amyloid β in the dentate gyrus and CA1 fields of the 
hippocampus, with distinctive expression patterns for each vector. Left panel: low magnification view of unilateral hippocam-
pus, scale bar 250 μm. Middle panel: higher magnification view of dentate gyrus (DG), scale bar 50 μm. Right panel: higher mag-
nification view of CA1, scale bar 50 μm.Molecular Neurodegeneration 2007, 2:11 http://www.molecularneurodegeneration.com/content/2/1/11
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than naïve controls (203 vs 130 lines, p < 0.01) indicating
higher baseline locomotor activity than other groups.
Naïve rats spent ~13% of their time in the open (center of
field) as did the BRI-Aβ40 animals, with a small reduction
in time spent in center field in both the BRI-Aβ42 and
APPsw groups relative to naive animals. The most marked
reduction in time spent in the open however, was in the
BRI-Aβ40+42 animals which spent on average only half
the amount of time in the open as naive controls (~6% vs
13%) (Figure 2B).
In the Morris water maze rats were required to learn the
location of the hidden platform over 5 training blocks,
with the start point varied between each trial so that the
task was difficult enough that differences in performance
would be measurable. As seen in Figure 3A, naïve animals
learned the location of the platform faster than AAV-treat-
ment groups, with naïve animals reaching a minimum
latency of ~18s by day 3 and not improving further
beyond that time. All Aβ treatment groups took longer to
reach the minimum latency than naïve controls, with the
most notable difference between groups on day 3 when
BRI-Aβ40+42 animals displayed an increased latency to
find the platform. Over all 20 acquisition trials, naive rats
had a mean latency of ~26 sec (Figure 3B), with all Aβ
treatment groups having longer latencies than this, partic-
ularly BRI-Aβ40+42 animals which performed the worst
overall with a mean latency over 20 trials of ~37s (ANOVA
P = 0.07). Repeated measures ANOVA on pathlength
taken to find the platform during the five days of acquisi-
tion training confirms the results obtained with latency
data. Overall the difference between treatment groups was
not significant (P = 0.061) (Figure 3C) but BRI-Aβ40+42
animals took a significantly longer mean pathlength to
find the platform over all 20 trials, Figure 3D (ANOVA P
= 0.02; BRI-Aβ40+42 > naïve, ** p < 0.01).
Animals were put through a probe trial 24 h after the last
training trial to check retention of spatial learning (Figure
3E, F). Naive animals spend ~30% of their time in the tar-
get quadrant, as did the BRI-Aβ42, BRI-Aβ40 and APPsw
animals. BRI-Aβ40+42 animals spent the least amount of
time and distance in the target quadrant of any treatment
group (~20%) indicating less retention of platform loca-
tion than in other groups. Results from the visible plat-
form test demonstrated that visibility was not impaired in
treated animals compared to naïve controls, with no dif-
ference in latencies to swim to a visible target (data not
shown).
In the passive avoidance test there was no difference in
baseline latencies to enter the dark chamber between the
treatment groups – on being placed in the light chamber
for the first time, animals took an average of ~18s to move
to explore the dark chamber, indicating no baseline differ-
ences in anxiety between treatment groups in this behav-
ioral test (Figure 4A). AAV-BRI-Aβ40 animals had a
significantly reduced latency to re-enter the dark chamber
24 hr after receiving a shock as compared to naïve controls
(~200s vs 500s, p < 0.05), indicating these animals had an
associational learning deficit. BRI-Aβ40+42 animals also
had a reduced latency (~240s vs 500s) to enter the dark
chamber but high variability between animals meant this
did not reach statistical significance. BRI-Aβ42 and APPsw
groups had reduced latencies (down by ~20% and 40%
respectively) but were not significantly different to con-
trols.
In the novel object recognition test, rats were habituated
to the test environment and then given two identical
objects to explore (O1, O2). In this first trial all groups
spent equal amounts of time exploring both objects, with
a ratio O2/O1 of ~1.2 for all groups. Rats were returned to
the test chamber 15 min later and presented with one
familiar (O3) and one novel (N) object. Animals in all
groups recognized and explored the novel object more
than the familiar object (with a ratio N/O3 of ~1.9–2.4 for
all groups) (Figure 4C). However it is noticeable that BRI-
Aβ40+42, BRI-Aβ42, and APPsw animals all spent less
total time (O1+O2+O3+N) exploring objects than naïve
controls (BRI-Aβ42 < naive, p < 0.05; APPsw < naïve, p <
0.01; Figure 4B) suggesting these animals are less inclined
to explore but can still recognize a novel object when
encountered. In this behavioral assay BRI-Aβ40 animals
were comparable to naïve controls, with similar explora-
tion times and similar ability to discriminate between
novel and familiar objects.
Overall, expressing APPsw or either one of the BRI-Aβ
fusions alone resulted in distinct cognitive deficits, but
interestingly animals expressing both Aβ species exhibited
more robust behavioral deficits.
Animals treated with AAV vectors encoding BRI-Aβ fusions 
have elevated Aβ levels
Animals were killed and the dissected hippocampus
examined for levels of RIPA-soluble and RIPA insoluble
FA-soluble Aβ peptides (either Aβ40 or Aβ42) by ELISA to
assess the levels of Aβ present at the time of behavioral
testing (Figure 5A). Naïve rats had negligible levels of
Aβ40 or Aβ42 in the hippocampus (all < 2 pmol/gm tis-
sue). AAV-BRI-Aβ40 injected animals had an increase in
both RIPA- and FA-soluble Aβ40 but no increase in RIPA-
or FA-soluble Aβ42. In AAV-BRI-Aβ42 animals there was a
marked increase in FA-soluble Aβ42 to ~72 pmol/gm but
only low levels of RIPA-soluble Aβ42 were detected in
these brains, suggesting that Aβ42 is accumulating in
insoluble deposits. Aβ40 levels (RIPA- or FA-soluble)
were not increased above baseline in AAV-BRI-Aβ42 ani-
mals suggesting an increase in Aβ42 production did notMolecular Neurodegeneration 2007, 2:11 http://www.molecularneurodegeneration.com/content/2/1/11
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influence endogenous Aβ40 levels. Animals injected with
the combination of BRI-Aβ40+42 vectors had higher lev-
els of RIPA-soluble and FA-soluble Aβ40 than naïve ani-
mals and an increase in FA-soluble Aβ42, but no increase
in RIPA soluble Aβ42. Interestingly, this level of insoluble
Aβ40 is higher than that observed in rats injected with
BRIAβ40 alone. AAV-APPsw animals had an increase in
the level of FA-soluble Aβ40 (14.3 pmol/gm vs none
detected in naïve) but levels of RIPA-soluble Aβ40 and
RIPA-soluble and insoluble Aβ42 were comparable to
naïve controls.
Deposition of Aβ plaques was detected only in 
hippocampus of AAV-BRI-Aβ42 rats
The other hemisphere from each brain was immunos-
tained with anti-Aβ to detect any deposits of Aβ. Only BRI-
Aβ42 animals showed "amorphous" plaque-like struc-
tures within the hippocampus following immunostaining
with pan anti-Aβ 1–16 antibody (Figure 5B). These depos-
its appeared to be diffuse, confirmed when they did not
stain with either thioflavin S or Congo Red (data not
shown). Even though there was evidence for significant
accumulation of RIPA-insoluble Aβ in the combined BRI-
Aβ40+42 expressing rats, these plaques were not seen in
the combined treatment group, any other treatment group
or the naïve controls. Immunostaining performed on
adjacent sections to those with plaque deposition in the
BRI-Aβ42 rats showed no evidence of phosphorylated tau,
astrogliosis or microgliosis in the vicinity of these diffuse
plaques.
Discussion
To better define the contribution of individual Aβ pep-
tides to the cognitive deficits and amyloid deposition
observed in models of AD, virally-mediated gene transfer
of BRI-Aβ fusion proteins was used to increase hippocam-
pal levels of individual Aβ species. Use of BRI-Aβ fusions
results in enhanced Aβ secretion in the absence of APP
overexpression, and distinguishes this approach from
overexpression of Aβ minigenes, a strategy that generates
high levels of intracellular Aβ but minimal secreted Aβ
[30]. Animals injected with AAV1 vectors encoding
APPsw, BRI-Aβ40 or BRI-Aβ42, alone and in combina-
tion, developed behavioral deficits in a distinct pattern.
AAV-APPsw and AAV-BRI-Aβ42 animals had reduced
exploration behavior during working memory evaluation
but no significant deficits in passive avoidance or acquisi-
tion and retention of spatial information. Animals
injected with AAV-BRI-Aβ40 alone were impaired in pas-
sive avoidance, but were comparable to age-matched
naive controls in the working memory task and were not
significantly impaired in the Morris water maze. However,
animals co-injected with both BRI-Aβ vectors showed the
most pronounced behavioral deficits with some impair-
ment in all tests. Despite measurable impairments occur-
ring in all groups, only BRI-Aβ42 animals developed
extracellular Aβ deposits. Taken together with the ELISA
and histology results, this behavioral data confirms obser-
vations from AD transgenic mouse models that measura-
ble behavioral deficits are not dependent on the presence
of Aβ plaques. Unexpectedly, the data shows develop-
ment of more pronounced cognitive deficits when Aβ42
and Aβ40 are co-expressed, and suggests a role for Aβ40,
along with Aβ42, in cognitive impairment.
In the current study only AAV-BRI-Aβ42 animals devel-
oped extracellular Aβ deposits, located within the hippoc-
ampus. These diffuse deposits were immuno-positive for
Aβ, but did not stain with thioflavin S or Congo Red and
were not associated with astrogliosis or proliferation of
microglia, indicating they are "non-cored" diffuse struc-
Behavior in the open field Figure 2
Behavior in the open field. 12 rats per group were used 
for behavioral testing. A. BRI-Aβ40+42 animals crossed sig-
nificantly more lines than naïve controls or any other treat-
ment group (ANOVA P = 0.027; BRI-Aβ40+42 > naïve, **p < 
0.01). B. Although overall there was no significant difference 
between treatment groups (ANOVA P = 0.24), BRI-
Aβ40+42 animals spent the least amount of time in the 
center of the field.Molecular Neurodegeneration 2007, 2:11 http://www.molecularneurodegeneration.com/content/2/1/11
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Morris water maze Figure 3
Morris water maze. A. Repeated measures ANOVA on latency to find the platform during acquisition shows that overall the 
difference between treatment groups was not significant (P = 0.12). However, naïve animals took fewer trials to learn the loca-
tion of the platform than AAV treatment groups, reaching a minimum latency by day 3. BRI-Aβ40+42 animals had a noticeably 
higher latency on day 3 of acquisition than other groups. B. BRI-Aβ40+42 animals had the highest mean latency over all 20 trials 
of all treatment groups (ANOVA P = 0.07). C. Repeated measures ANOVA on pathlength to find the platform during acquisi-
tion shows that overall the difference between treatment groups was not significant (P = 0.061). D. BRI-Aβ40+42 animals took 
a significantly longer pathlength to find the platform over all 20 trials (ANOVA P = 0.02; BRI-Aβ40+42 > naïve, ** p < 0.01). E, 
F. Animals were put through a probe trial 24 hr after the last training trial. BRI-Aβ40+42 animals showed a non-significant 
reduction in time (ANOVA P = 0.2) and distance (ANOVA P = 0.13) spent in the target quadrant.Molecular Neurodegeneration 2007, 2:11 http://www.molecularneurodegeneration.com/content/2/1/11
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tures. Expression for 9 months enhanced Aβ42 accumula-
tion but still did not result in formation of cored plaques
(not shown). Thus, these structures are similar to the dif-
fuse Aβ deposits observed in humans that are primarily
composed of Aβ42 and not associated with significant
reactive pathology. It is not clear why AAV-BRI-Aβ42 rats
A. Passive avoidance Figure 4
A. Passive avoidance. There was no difference in baseline 
latencies between the treatment groups (ANOVA P = 0.97) 
but at 24 hr BRI-Aβ40 animals had a reduced latency to re-
enter the dark chamber compared to naïve controls 
(ANOVA P = 0.03; BRI-Aβ40 < naive, *p < 0.05). B, C. 
Novel object recognition. At 3 months post-injection 
BRI-Aβ42, BRI-Aβ40+42 and APPsw animals spent less total 
time (O1+O2+O3+N) exploring than naïve controls (B) but 
still explored the novel object (N) more than the familiar 
object, O3 (C). Total exploration time: ANOVA P = 0.003; 
APPsw < naive, p < 0.01, BRI-Aβ42 < naïve, p < 0.05.
A. Characterization of Aβ levels in hippocampus by Aβ sand- wich ELISA Figure 5
A. Characterization of Aβ levels in hippocampus by 
Aβ sandwich ELISA. 12 rats per treatment were used for 
biochemical and histological analyses. Naïve rats have very 
low levels of either Aβ species. AAV-BRI-Aβ40 injected ani-
mals display an increase in both RIPA- and FA-soluble Aβ40 
at 3 months post-injection. There is a marked increase in FA-
soluble (RIPA-insoluble) Aβ42 in AAV-BRI-Aβ42 animals at 3 
months. B. Amyloid pathology in AAV-BRI-Aβ42 ani-
mals. Only BRI-Aβ42 animals showed diffuse plaque-like 
structures within the hippocampus following immunostaining 
with pan anti-Aβ 1–16 antibody. These deposits did not stain 
with thioflavin S or Congo Red (not shown). Magnification 
100x.Molecular Neurodegeneration 2007, 2:11 http://www.molecularneurodegeneration.com/content/2/1/11
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do not develop cored plaques. BRI-Aβ42 transgenic mice
develop cored plaques in the cerebellum as early as 3
months of age [4], and both diffuse and cored plaques in
the forebrain by 12 months of age. However, in those ani-
mals brain levels of insoluble Aβ42 were markedly higher
than the levels achieved in the current study. In contrast
Tg2576 (APP695SWE) mice, which have a high ratio of
Aβ40 to Aβ42, predominantly develop cored plaques
[7,9,31]. Brain-region or species specific factors might reg-
ulate Aβ aggregation into diffuse or cored: in humans cer-
tain regions of the brain seem more prone to develop
diffuse deposits of Aβ, and other factors such as ApoE [32-
35] and complement [36,37] may also play a role in driv-
ing amyloid formation. In any case, the current study
shows that viral delivery of BRI-Aβ42 can foster consider-
able Aβ accumulation in a relatively short time-frame, and
confirms both transgenic Aβ Drosophila [38] and trans-
genic BRI-Aβ mice studies [4] where visible Aβ deposits
were obtained only with Aβ42, but not Aβ40, overexpres-
sion.
The lack of correlation between presence of plaques and
severity of cognitive dysfunction observed in the current
study has been noted in a number of AD models [9,39-
41]. The current results are consistent with studies in
transgenic mice that demonstrate behavioral effects are
not correlated with visible plaques, but may correlate bet-
ter with other Aβ assemblies. Indeed, in Tg2576 mice the
appearance of behavioral deficits is associated with the
initial occurrence of insoluble Aβ accumulation at a time
when no overt plaque formation is noted [9,42-48]. In the
current study, overexpression of APPsw resulted in a pat-
tern of deficits similar to that observed in the BRI-Aβ42
group but with no deposition of plaques or detectable
increase in insoluble Aβ42, also consistent with data that
changes in morphologic markers of synaptic integrity
such as dendritic spine density and onset of behavioral
deficits can precede a measurable rise in insoluble Aβ42
levels [48].
Data obtained from the combined vector animals suggest
some interplay between Aβ40 and Aβ42 levels resulting in
enhanced behavioral deficits when the two peptides are
co-expressed. The level of insoluble Aβ40 is higher in the
BRI-Aβ40+42 animals than in those injected with AAV-
BRI-Aβ40 alone. Despite an absence of Aβ deposits that
are visible by immunohistochemistry, the presence of
SDS-insoluble, formic acid-soluble Aβ indicates that the
combined expression of Aβ40 and Aβ42 peptides does
lead to insoluble Aβ accumulation, perhaps indicating
seeding of Aβ40 deposition by Aβ42. Over-expressing
both Aβ40 and Aβ42 in the absence of other APP frag-
ments could result in production of a transient assembly,
or a structurally distinct aggregate, that affects behavior to
a greater degree than either peptide alone, as seen in a
recent study where cognitive dysfunction in Tg2576 mice
was linked to formation of a transient soluble assembly
[49]. The biochemical analysis of Aβ species described in
the current study were conducted prior to these recent
reports; thus, the material has been extracted in a manner
that would prevent analysis of Aβ * and other oligomeric
Aβ species. The behavioral impairments observed in the
combined vector treatment group could also be explained
by increased anxiety and locomotor behavior – in the
open field these animals crossed significantly more lines
and spent less time in the open than all other groups.
Increased anxiety itself could be indicative of altered hip-
pocampal functioning or damage [50-53].
The exact role of Aβ40 in cognitive impairment is cur-
rently unclear. In human patients high plasma concentra-
tions of Aβ40 are associated with an increased risk of
dementia [54] and along with Aβ42, Aβ40 is known to
impair hippocampal LTP in rats [55-57] and to alter gluta-
mate receptor composition and trafficking and synaptic
function [58,59]. However, studies to date on specific
effects of Aβ on cognitive function in mammalian brain
have relied on non-specific pharmacological intervention
to increase Aβ levels [60] or infusion of Aβ peptides
directly into the hippocampus or ventricles [61-63] rather
than the prolonged and more physiologic secretion strat-
egy adopted here. The pathology of transgenic BRI-Aβ40
and BRI-Aβ42 mice has been characterized [4], but the
behavioral phenotype of these animals has not been
reported, and to date no behavioral phenotype has been
detected (E. McGowan, T. Golde, C. Janus personal com-
munication). A recent study of transgenic Drosophila sup-
ported a role for both Aβ40 and Aβ42 in age-dependent
learning defects [38], with a higher level of Aβ40 than
Aβ42 required to affect learning ability. Our data confirm
a potential role for both Aβ40 and Aβ42 in altering cogni-
tive impairment that, at least for Aβ40, appears to be dis-
sociable from overt plaque formation. The effects of Aβ40
and Aβ42 in AAV-BRI-Aβ treated rats may reflect altera-
tions in glutamate receptors and synaptic assemblies, and
future work will include examination of synaptic markers,
NMDA receptor composition and PSD95 levels.
Conclusion
Overall, the results demonstrate that both Aβ40 and
Aβ42, not just Aβ42 alone, may contribute to the develop-
ment of distinct cognitive deficits in rats as co-expression
of Aβ40 and Aβ42 produced a more robust behavioral
phenotype then expression of either Aβ peptide alone.
The lack of correlation between severity of behavioral def-
icits and presence of Aβ deposits confirms previous stud-
ies of mouse transgenic models in which cognitive deficits
precede visible Aβ deposition, but are associated with the
accumulation of detergent insoluble Aβ. These results
demonstrate that increasing Aβ levels by AAV-mediatedMolecular Neurodegeneration 2007, 2:11 http://www.molecularneurodegeneration.com/content/2/1/11
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gene transfer, allowing spatial and temporal regulation of
specific Aβ species, is a valuable tool to study AD patho-
genesis.
Methods
Study outline
AAV1 vectors encoding APPsw, BRI-Aβ42 and BRI-Aβ40
were generated and injected into the hippocampus of
adult rats. Transgene expression was confirmed immuno-
histochemically in a group of test animals (n = 3 per vec-
tor). The effects of long-term over-expression of BRI-Aβ42,
BRI-Aβ40, combined BRI-Aβ42 + BRI-Aβ40, or APPsw in
the rat hippocampus were assessed, with animals tested 3
months post-infusion for development of cognitive defi-
cits and brain tissue examined for Aβ levels and presence
of AD pathology (n = 12 per group).
Expression constructs
cDNAs for APPsw (gift of D Selkoe) and BRI-Aβ fusions
[29] were sub-cloned into an AAV expression plasmid
under the control of a CBA (chicken beta-actin) promoter
and containing a SAR (scaffold attachment region) ele-
ment, WPRE (woodchuck hepatitis virus post-transcrip-
tional-regulatory element), and bovine growth hormone
polyadenylation signal flanked by AAV2 inverted terminal
repeats (ITRs).
Generation of AAV vectors
HEK293 cells were co-transfected with AAV and helper
plasmids using standard CaPO4 transfection. Cells were
harvested 60 hr following transfection, and AAV1 vectors
purified from the cell lysate by ultracentrifugation
through an iodixanol density gradient followed by Q col-
umn purification, then concentrated and dialysed against
PBS [64,65]. Vectors were titered using real-time PCR (ABI
Prism 7700) and all vector stocks diluted to 1 × 1013
genomes/ml.
Infusion of vectors
Animal studies were approved by The University of Auck-
land Animal Ethics Committee, and rats supplied by the
Animal Resources Unit, The University of Auckland. 250–
300 g male Wistar rats were used for all studies. Animals
were anaesthetized with sodium pentobarbitone (Nemb-
utal, Virbac Laboratories, 90 mg/kg, i.p.) and placed in a
Kopf stereotaxic frame. AAV1 vectors were infused bilater-
ally into the hippocampus at the following stereotaxic co-
ordinates: flat skull – anterior-posterior (AP) -4.0 mm, lat-
eral (L) 2.1 mm, and ventral (V) 4.5 mm from skull sur-
face, bregma = zero). 3 μl vector (3 × 1010 genomes) was
infused into each side at 70 nl/min. Animals receiving
both BRI-Aβ vectors still received a total of 3 × 1010
genomes in 3 μl (1.5 × 1010 genomes of each vector) into
each side.
Behavioral testing
All animals were pre-handled for 7 days prior to testing
and tests were carried out in the order described. All tests
were conducted by an experimenter blinded to the treat-
ments.
Open field
Movement in an open field was used to assess whether
AAV treatments had an effect on locomotor ability or anx-
iety, either of which may affect learning and memory
behaviors. Rats were placed in the center of a 1.8 m circu-
lar field divided into segments and allowed to move freely
for 5 min. The number of lines crossed and amount of
time spent within 20 cm of the perimeter were recorded as
measures of locomotor ability and anxiety. Time not
spent at the perimeter was defined as time spent "center
field".
Morris water maze
This test was used as a measure of spatial learning – the rat
must learn the location of a hidden platform by referring
to visual cues placed around the room. The platform loca-
tion was kept constant throughout training but the start-
ing point varied pseudorandomly between trials, with all
four start points used in each training block to ensure all
rats had to swim the same distance each day. The water
maze consists of a circular pool (1.8 m diameter and 0.6
m height) filled to a depth of 27 cm with 26 ± 1°C water.
The escape platform is 17 cm in diameter and submerged
2 cm below the surface of the water. A small amount (5
ml) of non-toxic black textile dye was added to the water
to camouflage the platform. Visual cues (black cardboard
shapes on white curtains) were placed around the room
and remained constant throughout testing, removed only
for the visible platform test at the end of the run.
The test procedure consisted of three parts; acquisition
training, a probe (retention) trial, and visible platform
training. Acquisition training took place over 5 days, with
each rat given four trials per day. A trial consisted of allow-
ing the rat 90 sec to find the platform (if not located in this
time then the animal was guided to the platform by the
experimenter). The rat remained on the platform for 30
sec before being returned to the home cage for 60 sec,
when the next trial began. The latency and pathlength to
find the hidden platform were recorded for each trial
using Watermaze 4.0 Software.
On day six animals underwent a retention (probe) trial –
the platform was removed from the pool (visual cues still
visible) and the animal allowed to swim for 30 sec. Time
spent in the quadrant of the pool that previously held the
platform (target quadrant) was measured. On day seven
animals underwent visible platform training – visual cues
were removed from the wall and the platform placed in aMolecular Neurodegeneration 2007, 2:11 http://www.molecularneurodegeneration.com/content/2/1/11
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different quadrant, raised above the waterline so it was
clearly visible to the rat. The time taken by the rat to swim
to the visible platform was recorded. This was to ensure
that any observed deficits in learning were not merely the
result of poor eyesight.
Passive avoidance
This was used as a test of associational learning. Equip-
ment consisted of two identical chambers (one well-lit,
the other dark) connected via a guillotine door. Rats were
placed in the light chamber and (baseline) time to enter
the dark chamber recorded. The door was closed and the
animal received a small electrical shock (1.0 mA for 3 sec)
whilst in the dark chamber and 10s later was returned to
the home cage. Animals were returned to the light cham-
ber 24 hr later and latency to enter the dark chamber was
recorded to a maximum of 600s.
Novel object recognition
This working memory test is based on the rat's natural
propensity to explore novel objects. The test chamber con-
sisted of a perspex box (dimensions 85 × 60 × 50 cm). Rats
were given two days to habituate to the test environment
– on days one and two animals were placed in the test
chamber for 5 min with no objects to explore. On day
three the rat was placed in the test chamber now contain-
ing two identical objects (O1 and O2; objects never
encountered before and of no natural significance). The
rat was placed equidistant from the two identical objects
and the time spent exploring each object (nose within 2
cm of object) recorded for 3 min. The rat was returned to
the test chamber 15 min later and given one familiar (O3)
and one novel (N) object to explore. Time spent exploring
each object was recorded over 3 min.
Statistical analyses
Behavioral data was analyzed using ANOVA (repeated
measures where appropriate) with Dunnett's post-hoc
analysis.
Tissue collection
Test rats (used to confirm transgene expression) were
euthanised with pentobarbitone and perfused transcar-
dially with 60 ml saline followed by 60 ml 4% parafor-
maldehyde in 0.1 M phosphate buffer (PFA). Brain tissue
was post-fixed for 24 h in 4% PFA, cryoprotected in
increasing concentrations (10, 20, 30%) of sucrose in PBS
and cut into 40 μm free-floating sections using a cryostat.
All other rats were sacrificed one week after the conclusion
of behavioral testing – animals were euthanised with
pentobarbitone and brains removed and dissected longi-
tudinally. One hemibrain was post-fixed in 4% PFA and
used for immunohistochemical and histological analyses;
the other half was frozen immediately on dry ice and used
for Aβ ELISAs.
Immunohistochemistry
Sections from transgene expression brains were immu-
nostained with anti-Aβ 1–17 (Chemicon MAB1560,
6E10, specific to human Aβ 1–17) according to the fol-
lowing protocol. Sections were washed in 1 × PBS con-
taining 0.2% Triton (PBS-T), and incubated in 1% H2O2
in 50% methanol for 30 min to bind endogenous peroxi-
dase present in the tissue. Sections were washed exten-
sively in 1 × PBS-T, then treated with 70% formic acid for
30 min and again washed in PBS-T. 200 μl of primary
antibody diluted 1:1500 in immunobuffer (1 × PBS-T
containing 1% normal goat serum, 0.4 mg/ml methi-
olate) was applied overnight at room temperature on a
rocking table. The following day sections were washed in
1 × PBS-T and incubated in 200 μl of biotinylated anti-
mouse (Sigma; diluted 1:250 in immunobuffer) for 3 hr
at room temperature. Following further washes in 1 ×
PBS-T, sections were incubated in 200 μl ExtrAvidin Per-
oxidase (Sigma; diluted 1:250 in immunobuffer) for 2 hr
at room temperature. Sections were washed in PBS-T and
antibody binding was visualised using 3', 3-diaminoben-
zidine (DAB; Sigma, St. Louis, MO) at 0.5 mg/ml DAB in
0.1 M phosphate buffer with 0.01% H2O2.
Hemibrains from long-term animals were post-fixed in
4% PFA and stained for Aβ plaques as described previ-
ously [66]. Paraffin sections (5 μm) were pretreated with
80% formic acid (FA) for 5 minutes, boiled in water using
a rice steam cooker, washed, and immersed in 0.3% H2O2
for 30 minutes to block intrinsic peroxidase activity. Sec-
tions were then incubated with 2% normal goat serum in
PBS for 1 hour, with 33.1.1 (Pan Aβ 1–16 mAb) at 1 μg/
ml dilution overnight, and then with HRP-conjugated
goat anti-mouse secondary mAb (1:500 dilution; Amer-
sham Biosciences) for 1 hour. Sections were washed in
PBS, and immunoreactivity was visualized by DAB
according to the manufacturer's specifications (ABC sys-
tem; Vector Laboratories). Adjacent sections were stained
with 4% thioflavin-S for 10 minutes. Additional sections
were immunostained for activated microglia using anti-
Iba1 (1:3000; Wako Chemicals); astrocytes using anti-
GFAP (1:1000, Chemicon); phosphorylated tau with
CP13 (1:100) and PHF-1 (1:100; kindly provided by Dr
Peter Davies, Albert Einstein School of Medicine, Bronx,
NY).
Aβ ELISA
Rat hippocampal and cerebellar tissue was homogenized
in radio-immunoprecipitation assay (RIPA) buffer and
ultracentrifuged to separate RIPA-soluble from insoluble
fractions. RIPA-insoluble proteins were extracted using
70% FA, neutralized with Tris base buffer and samples
diluted (from 10–5000-fold). Extracted Aβ was then
measured using a sandwich ELISA system as described
previously [66] – Aβ42 capture with mAb 2.1.3Molecular Neurodegeneration 2007, 2:11 http://www.molecularneurodegeneration.com/content/2/1/11
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(mAb40.2,) and detection with HRP-conjugated mAb
Ab9 (human Aβ 1–16 specific); Aβ40 capture with mAb
Ab9 and detection with HRP-conjugated mAb 13.1.1
(mAβ40.1).
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